期刊文献+

Risk of cardiovascular death in patients with hepatocellular carcinoma based on the Fine-Gray model

下载PDF
导出
摘要 BACKGROUND Hepatocellular carcinoma(HCC)is one of the most common types of cancers worldwide,ranking fifth among men and seventh among women,resulting in more than 7 million deaths annually.With the development of medical tech-nology,the 5-year survival rate of HCC patients can be increased to 70%.How-ever,HCC patients are often at increased risk of cardiovascular disease(CVD)death due to exposure to potentially cardiotoxic treatments compared with non-HCC patients.Moreover,CVD and cancer have become major disease burdens worldwide.Thus,further research is needed to lessen the risk of CVD death in HCC patient survivors.METHODS This study was conducted on the basis of the Surveillance,Epidemiology,and End Results database and included HCC patients with a diagnosis period from 2010 to 2015.The independent risk factors were identified using the Fine-Gray model.A nomograph was constructed to predict the CVM in HCC patients.The nomograph performance was measured using Harrell’s concordance index(C-index),calibration curve,receiver operating characteristic(ROC)curve,and area under the ROC curve(AUC)value.Moreover,the net benefit was estimated via decision curve analysis(DCA).RESULTS The study included 21545 HCC patients,of whom 619 died of CVD.Age(<60)[1.981(1.573-2.496),P<0.001],marital status(married)[unmarried:1.370(1.076-1.745),P=0.011],alpha fetoprotein(normal)[0.778(0.640-0.946),P=0.012],tumor size(≤2 cm)[(2,5]cm:1.420(1.060-1.903),P=0.019;>5 cm:2.090(1.543-2.830),P<0.001],surgery(no)[0.376(0.297-0.476),P<0.001],and chemotherapy(none/unknown)[0.578(0.472-0.709),P<0.001]were independent risk factors for CVD death in HCC patients.The discrimination and calibration of the nomograph were better.The C-index values for the training and validation sets were 0.736 and 0.665,respectively.The AUC values of the ROC curves at 2,4,and 6 years were 0.702,0.725,0.740 in the training set and 0.697,0.710,0.744 in the validation set,respectively.The calibration curves showed that the predicted probab-ilities of the CVM prediction model in the training set vs the validation set were largely consistent with the actual probabilities.DCA demonstrated that the prediction model has a high net benefit.CONCLUSION Risk factors for CVD death in HCC patients were investigated for the first time.The nomograph served as an important reference tool for relevant clinical management decisions.
出处 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第3期844-856,共13页 世界胃肠肿瘤学杂志(英文版)(电子版)
基金 Health Technology Project of Tianjin,No.ZC20175.
  • 相关文献

参考文献2

二级参考文献47

  • 1Shu-Guang Zheng,Hui-Xiong Xu,Lin-Na Liu.Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound[J].World Journal of Radiology,2014,6(1):7-14. 被引量:20
  • 2Okuda K, Kondo Y. Primary carcinomas of the liver. In: Haubrich WS, Schaffner F, Berk JE, eds. Gastroenterology Volume 3.5^th ed. Philadelphia: W. B. Saunders 1995:2467-2468.
  • 3Wu JC, Daughaday WH, Lee SD, Hsiao TSY, Chou CK, Lin HD,Tsai YT, Chiang BN. Radioimmunoassay of serum IGF-Ⅰ and IGF-Ⅱ in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. J Lab Clin Med 1988; 112:589-594.
  • 4Hwang SJ, Lee SD, Chang CF, Wu JC, Tsay SH, Lui WY, Chiang JH, Lo KJ. Hypercholesterolemia in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1992; 7:491496.
  • 5Yen TC, Hwang SJ, Wang CC, Lee SD, Yeh SH. Hypercalcemia and parathyroid hormone-related protein in hepatocellular carcinoma. Liver 1993; 13:311-315.
  • 6Hwang SJ, Lee SD, Wu JC, Chang CF, Lu CL, Tsay SH, Lo KJ.Clinical evaluation of erythrocytosis in patients with hepatocellular carcinoma. Chin Med J 1994; 53:262-269.
  • 7Luo JC, Hwang SJ, Li CP, Hsiao LT, Lai CR, Chiang JH, Lui WY,Chang FY, Lee SD. Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan. Cancer 1999; 86:799-804.
  • 8Nickerson HJ, Silberman TL, McDonald TP. Hepatoblastoma,thrombocytosis, and increased thrombopoietin. Cancer 1980;45:315-317.
  • 9Shafford EA, Ritchard JP. Extreme thrombocytosis as a diagnostic clue to hepatoblastoma. Arch Dis Child 1993; 69:171-174.
  • 10Komura E, Matsumura T, Kato T, Tahara T, Tsunoda Y,Sawada T. Thrombopoietin in patients with hepatoblastoma.Stem Cells 1998; 16: 329-333.

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部